<DOC>
	<DOCNO>NCT01779687</DOCNO>
	<brief_summary>Dyslipidemia highly prevalent among patient HIV infection contributes increase cardiovascular disease risk patient population . Atorvastatin lower plasma low-density lipoprotein ( LDL ) cholesterol level use prevention artherosclerotic disease . Raltegravir , HIV integrase inhibitor , could one preferred antiretroviral agent HIV patient dyslipidemia beneficial lipid profile . Theoretically , clinically relevant drug interaction expect atorvastatin raltegravir . However , atorvastatin raltegravir share similar metabolic pathway could relevant occurrence pharmacokinetic interaction . In order able recommend raltegravir atorvastatin concomitant use , pharmacokinetic study healthy volunteer propose .</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study Between Raltegravir Atorvastatin .</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subject least 18 old 55 year screen . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior first dose . Results biochemistry , haematology urinalysis test within laboratory 's reference range . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . Subject normal blood pressure pulse rate , accord Investigator 's judgement . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Pregnant female ( confirm hCG test perform less 4 week day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct study . Therapy drug ( two week precede dose ) , except acetaminophen . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder , musculoskeletal connective tissue disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent study procedure require . Participation drug study within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>interaction</keyword>
	<keyword>cholesterol</keyword>
	<keyword>raltegravir</keyword>
	<keyword>atorvastatin</keyword>
</DOC>